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Immunohistochemistry and immunofluorescence 
Prior to necropsy, mice were injected with 0.1 mg BrdU/g for two hours. Tissues were fixed 
in 4% paraformaldehyde. Antigen retrieval of serial sections was performed by heating in 10 
mM Tris, 1 mM EDTA (pH 9.0). Antibodies used for immunohistochemistry and 
immunofluorescence are in Suppl. Table 2. Staining was detected with the streptavidin-
peroxidase method (Dako) or Alexa488- (Molecular Probes), Cy2- or Cy3- (Jackson Immuno 
Research) conjugated secondary antibodies. 
 
Cell proliferation and collagen assays of primary cells 
For 2D-collagen assays, 96-well plates were coated with 50 μl collagen matrix (DMEM/F12 
containing 1.5 mg/ml collagen solution (Sigma-Aldrich), 2.2 mg/ml NaHCO3, 20 mM Hepes, 
5% FCS). 1x10
3 
cells in 100 µl Opti-MEM were seeded overnight onto collagen coated wells. 
Cells were treated with 17β-estradiol or tamoxifen (Sigma-Aldrich), dissolved in ethanol at a 
final concentration of 0.1%, suspended in DMEM/F12 media containing 5% FCS, 20 ng/ml 
mEGF, 5 µg/ml insulin, and 1% penicillin-streptomycin. 
 
Wnt Reporter assays 
TOP/FOP reporter activity was determined following knockdown of BCL9-2 or β-catenin in 
MCF7 and T47D. Cells were pre-transfected with siRNAs for 48 hours followed by 
transfection with 100 ng TOP or FOP luciferase reporters and 25 ng tk-Renilla controls for 
additional 24 hours. For TOP/FOP reporter assays after overexpression of BCL9-2 or β-
catenin, cells were transfected with 100 ng β-catenin or 200 ng BCL9-2 expression plasmids, 
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100 ng TOP or FOP reporter and 25 ng tk-Renilla control for 48 hours followed by treatment 
with Wnt3a- or control-conditioned media produced in L cells (ATCC) for additional 24 
hours. Firefly luciferase values were normalized to Renilla controls. 
 
Chromatin immunoprecipitation (ChIP), re-ChIP and Immunoprecipitation  
ChIP and re-ChIP assays on MCF7 were performed after chromatin crosslink with 1% 
formaldehyde and sonification on a Diagenode BioRuptor (3-times  30 cycles of 10 sec on/off 
at high power) using the EZ-ChIP Kit (Merck Millipore) according to manufacturer`s 
protocol. For ChIP assays after mithramycin A treatment, MCF7 were pretreated 24 hours 
either with 0.1% EtOH as vehicle or 100 nM mithramycin A (Sigma). The elution of DNA 
and reverse protein/DNA crosslink was performed using Chelex-resin solution (Bio-Rad 
Laboratories) or using IPure kit (Diagenode) according to manufacturer`s protocol. Mouse 
and rabbit IgG (m IgG, rb IgG) were used as negative controls and for the normalization of 
the amplified signals. The fold enrichment was calculated as percent of input DNA. For co-
IP’s, cells were incubated on ice in RIPA buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 
mM EDTA, pH 8; 1% NP40; 0.25% Na-desoxycholate) containing 1x protease inhibitor 
cocktail (Roche). After centrifugation, the supernatants were incubated with the respective 
antibodies and Protein G sepharose (GE Healthcare) according to standard protocols. The 
immunoprecipitated proteins complexes were analyzed by Western Blot. ChIP experiments 
and co-immunoprecipitation were repeated at least three times. Primary antibodies are in 
Suppl. Table 2. Primers for PCR and qRT-PCR analysis of the precipitated chromatin 
complexes are provided in Suppl. Table 3. 
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Immunoreactive scores 
BCL9 and BCL9-2 scores were calculated for the intensity and percentage of positive 
epithelial cells as previously described [1; 2]. Staining for nuclear ER and PR were scored 
according to the Remmele score [3] (IRS 0-12). Membranous Her2 scores were from 0 to 3+. 
Tissues with scores of 0 and 1 for ER, PR, or Her2 respectively were evaluated as negative, 
the cases with higher scores as positive, according to the European guidelines for quality 
assurance in breast cancer screening and diagnosis (4
th
 edition, 2006). 
 
GEO Data analysis 
The Gene Expression Omnibus (GEO) GSE6532 dataset [4] with normalized gene expression 
values of human Affymetrix arrays was retrieved from the NCBI data repository. The dataset 
was created from early stage patients with ER+ breast cancers and provides information of ER 
positivity, tamoxifen treatment, and patient’s survival. Array data from 263 tamoxifen treated 
patients were grouped as high or low relative to the median gene expression of BCL9-2 
(228065_at). 
 
Statistical methods 
Box Plot analyses were performed for the scores of preneoplastic tissue changes and the 
immunoreactive scores and the significances were calculated using the Mann-Whitney U-test 
provided by the SPSS package 19. Cumulative hazard for the risk of breast tumors of mice 
were determined by Kaplan-Meier analysis using SPSS 19. Frequency of mammary tumor 
development in the mouse models were analyzed by the Chi-Square Test (Suppl. Table 1) and 
graphs for the dose-response of primary control and BCL9-2 tumor cells were plotted after 
nonlinear regression analysis using Graph Pad Prism 5. Survival analysis for relapse free 
patient survival was analyzed by Kaplan-Meier plots and significance was calculated using 
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the Cox Proportional Hazards Model with the free statistical software R (version 2.14.1). For 
all other experiments, graphs were calculated as means ± SEM and statistics were evaluated 
by the Student’s t-test using Microsoft Excel. P-values of <0.05 were considered to be 
statistically significant. 
 
Image acquisition 
Immunostains were visualized on a Leica DM5000 B upright microscope with 20x and 40x 
objectives, colonies from 2D-collagen assays on a Leica DM IRB inverted microscope with a 
10x objective and Carmine whole mount stains on a Leica MZ FLIII stereo microscope at 
1.25fold magnification (Leica Microsystems). All bright field images were acquired with a 
DFC290 HD camera with the settings provided by the Leica Application Suite Software LAS 
Version 3.8. Images of immunofluorescence stains were captured with a DC300 FX camera 
using Leica Application Suite Software LAS Version 2.8.1 and image overlay processed with 
the LAS Image Overlay module. 
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Supplemental Figure 1: Expression analysis of BCL9 and BCL9-2 in human breast 
cancers and normal mammary tissues.(A) Example of the immunostains for BCL9 and 
BCL9-2 on a human breast tissue microarray (BRC481, Pantomics) containing matched 
specimens of cancer tissues and adjacent normal tissue. (B) Box plot analysis for the BCL9 
and BCL9-2 immunoreactive scores of the same tissue array from adjacent normal breast 
tissues (N; n=12) and breast cancer samples (CA; n=24).(C)  Immunofluorescence stains of 
BCL9-2, ER and SMA and merged pictures of an additional example for ER+ human breast 
cancer. (D-F) Representative images of immunostains of large ducts (upper panels) and 
alveoli (lower panels) in the mammary gland from pregnant wild-type C57BL/6 mice (D), 20 
month old non-transgenic (E) and age-matched BCL9-2 transgenic females (F). As negative 
controls immunostains without primary antibody were performed. Tissues were stained with 
the respective primary BCL9 or BCL9-2 antibodies and competition of the staining was 
performed with the immunopeptides utilized for antibody production (1 µg peptide/ml 
antibody solution). Scale bars in the pictures represent 50 µm. Inserts show the staining at 
higher magnification. 
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Supplemental Figure 2: Aged BCL9-2 transgenic mice develop ER+ breast cancers. 
(A) Additional example for the ductal-like breast tumors from BCL9-2 transgenic female 
mice. Tissue sections were stained by H&E and with the indicated antibodies for cell specific 
markers.(B) Additional co-immunofluorescence stains for the indicated markers of epithelial 
and mesenchymal cells in an example of the ductal-like BCL9-2 tumors.(C) Example of a 
lobular-like breast tumor from BCL9-2 transgenic mice. Tissue sections were stained by H&E 
and with the indicated antibodies.Scale bars in the figures represent 200 µm (H&E) and 50 
µm for IHC or IF. Inserts show the staining at higher magnification. 
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Supplemental Figure 3: Analyses of primary breast tumor cells from BCL9-2 transgenic 
mice .(A) Additional immunofluorescence stains of primary cells established from mammary 
tumors of BCL9-2 females. Cells were stained with the indicated antibodies. Scale bar: 50 
µm. (B) Western Blots (WB) of cell lysates after co-immunoprecipitation (IP) in primary 
BCL9-2 tumor cells with the indicated antibodies. Mouse and rabbit IgG's were used as 
negative controls. 
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Supplemental Figure 4: Analyses of endogenous BCL9 and Pygo proteins in breast 
cancer cells and RNA interference against BCL9-2 and ß-catenin. (A) Western Blot 
analyses for endogenous BCL9/BCL9-2, Pygo1/2, ERα and ß-catenin protein in whole cell 
lysates obtained from the indicated human breast cancer cell lines. Blots were reprobed with 
α-tubulin as loading controls. Lysates from wild-type HEK293 cells and transiently 
transfected for the respective proteins (indicated by an asterisk) were used as negative and 
positive controls.(B, C) RNA interference against BCL9-2 and ß-catenin with On-Target Plus 
siRNA pools (si 1-4) and the single siRNAs (50 nM) in human cancer cells. Based on the 
qRT-PCR results, the two most effective siRNAs were further used as pool at a final 
concentration of 50 nM in all experiments. Graphs show the mean of at least three qRT-PCRs 
and of their standard error, relative to control siRNA-treated cells. Significant differences are 
indicated by an asterisk for P<.05.(D) Densitometry of Western blot analyses from at least 
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three independent experiments after BCL9-2 knockdown as presented in Figure 6D. The 
protein levels were normalized to the respective loading controls (Lamin B for nuclear and α-
tubulin for cytoplasmatic fractions) and calculated relative to the vehicle treated cells 
transfected with control siRNAs. 
 
Supplemental Figure 5: BCL9-2 regulates ER expression and interacts with Sp1 in 
human T47D breast cancer cells. (A) Co-immunofluorescence stains for BCL9-2, ER and ß-
catenin in T47D cells. The scale bar represents 50 µm. (B, C) The effects of BCL9-2 
knockdown on ER expression in T47D breast cancer cells. Cells were pre-treated for 48 hours 
with the indicated siRNAs followed by hormone starvation overnight. (B) qRT-PCR analysis 
of the indicated genes and (C) luciferase activity of the ER responsive elements reporter 
(ERE-luc) in T47D cells after downregulation of BCL9-2 followed by treatment with or 
without 10 nM estrogen for 6 or 24 hours. * and ** indicates significant differences for P 
<.05 and P <.001. Graphs show the mean of at least three independent experiments and of the 
standard error, relative to control siRNA-treated cells.(D) Western Blots (WB) analyses of 
cell lysates after co-immunoprecipitation (IP) in T47D cells with the indicated antibodies. As 
control, mouse and rabbit IgG’s were used. 
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Supplemental Figure 6: Canonical Wnt/ß-catenin signaling is inactive and β-catenin 
does not affect ER expression in human ER+ cancer cells. (A, B) Relative luciferase 
activity of the TOP/FOP Wnt-reporter in MCF7 and T47D cells after downregulation of 
BCL9-2 and β-catenin (A) and in MCF7 cells after overexpression of BCL9-2 and ß-catenin 
with and without Wnt 3a stimulation (B).  (C, D) The effects of β-catenin knockdown on ER 
expression in MCF7 cells. Cells were pre-treated for 48 hours with the indicated siRNAs, 
followed by hormone starvation overnight and treatment with 10 nM estrogen (+E2) or 
vehicle alone (-E2) for additional 6 or 24 hours. Graphs in A-D show the mean of at least 
three independent experiments and of their standard error, relative to control siRNA-treated 
cells. Significant differences are indicated with * for P<.05 and ** for P<.01; n.s. = not 
significant. Luciferase activity of a reporter containing optimal ER responsive elements 
(ERE-luc) in MCF7 cells after downregulation of β-catenin followed by treatment with or 
without estrogen for 6 hours (C). qRT-PCR analysis of the RNA expression of the indicated 
genes after knockdown of β-catenin followed by treatment with or without estrogen for 6 
hours (left bars) and 24 hours (right bars) (D). (E) Representative Western Blots of nuclear 
and cytoplasmatic (cyt.) fractions after β-catenin knockdown and 24 hours of estrogen 
treatment. Lysates were probed with the indicated antibodies. LaminB1 and alpha-tubulin 
antibodies were used as loading controls. (F) The effects of β-catenin knockdown on 
proliferation of MCF7 cells as determined by BrdU incorporation assays. Representative time 
course experiment performed in triplicates and the range for each time point, relative to the 
indicated control. MCF7 cells were pre-treated with the indicated siRNAs for 48 hours. Cells 
were further hormone starved overnight, followed by treatment with and without 1 µM E2 for 
the indicated time points. 
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Supplemental Table 1:Frequencies of macroscopic mammary tumors of K19-BCL9-2 
transgenic females.Development of macroscopic mammary tumors of BCL9-2 animals from 
different founder lines, virgins and parous animals compared to age matched non-transgenic 
controls and C57BL/6 controls. Animals were monitored for mammary tumor development 
until the age of 24 month. Statistic differences for K19-BCL9-2 animals compared to the 
respective controls were calculated with the one-sided Chi-square test (2) with and without 
Yates' continuity correction. 
 
mouse strain animals breast tumors 2 2 
with Yates' 
correction 
  n n % p p 
non-transgenic controls 34 0 0   
K19-BCL9-2 transgenic 
(all founder lines) 
109 20 18 0.0035 0.0080 
K19-BCL9-2 virgins 
K19-BCL9-2 parous 
82 
27 
13 
7 
16 
26 
0.0069 
0.0008 
0.0162 
0.0030 
K19-BCL9-2 line # 1 
K19-BCL9-2 line # 2 
K19-BCL9-2 line # 3 
K19-BCL9-2 line # 4 
K19-BCL9-2 line # 5 
K19-BCL9-2 line # 6 
18 
19 
14 
25 
4 
29 
3 
4 
2 
5 
1 
5 
17 
21 
14 
20 
25 
17 
0.0071 
0.0027 
0.0122 
0.0032 
0.0016 
0.0058 
0.0338 
0.0125 
0.0726 
0.0121 
0.0962 
0.0199 
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Supplemental Table 2:Antibodies used in this study for immunohistochemistry (IHC), 
immunofluorescence (IF), Western Blot (WB), co-immunoprecipitation (IP) and Chromatin- 
Immunoprecipitation (ChIP). 
Antibody  Host Source Application 
BCL9 
BCL9-2 
BCL9-2 
Pygo1 
Pygo2 
rabbit 
rabbit 
rabbit 
rabbit 
rabbit 
Brembeck et al., 2011 
A303-152A, Bethyl Lab. 
Brembeck et al., 2011 
Brembeck et al., 2011 
Brembeck et al., 2011 
IHC, WB 
IP, ChIP, WB 
IHC, IF, WB 
WB 
WB, IP, ChIP 
β-catenin 
β-catenin 
rabbit 
mouse 
Brembeck et al., 2004 
610154, BD Biosciences 
IHC, IF, WB, IP, ChIP 
IF, IP, ChIP 
Flag mouse A 8592 M2, Sigma-Aldrich WB 
ERα 
ERα 
rabbit 
mouse 
sc-7207 H-184, Santa Cruz 
EI651C0, DCS 
IHC, IF, WB, IP 
IF 
panCK mouse C2562 C11, Sigma-Aldrich IHC, IF 
E-cadherin mouse  610182, BD Biosciences  IHC, WB 
αSMA mouse A2547 1A4, Sigma-Aldrich IHC, IF 
K19 
K19 
rabbit 
rabbit 
ab15463, Abcam 
ab76539, Abcam 
IHC 
IHC, IF 
P63 mouse  PI006C002, DCS IF 
PR rabbit sc-539 C-20, Santa Cruz  IHC, WB 
Her2 rabbit sc-284 C-18, Sigma-Aldrich IHC 
BrdU rat ab6326, Abcam IHC 
Cleaved caspase 3 rabbit 9661L, Cell Signaling  IHC 
LaminB1 goat sc-6216 C-20, Santa Cruz  WB 
α-tubulin mouse T 9026 DM 1A, Sigma-Aldrich WB 
Sp1 rabbit 07-645, Merck Millipore WB, ChIP 
Pol II mouse 05-623 CTD4H8, Merck 
Millip. 
ChIP 
Normal Mouse IgG mouse 12-371, Merck Millipore ChIP  
p53 rabbit sc-6243 FL-393, Santa Cruz WB, ChIP, IP 
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Supplemental Table 3: Primer sequences used in this study for PCR, quantitative Real-time 
PCR (qRT-PCR) and cloning. fwd= forward, rev=reverse sequence, h=human, m=mouse, 
p=promoter. 
Primer Sequence (5’-3’) Application 
transgene fwd 5’- CAAGGACGACGACGACAAGG  PCR 
transgene rev 5’- CTCTGAATCGAGGGATGGAG  PCR 
m+h actin fwd 5’- GCACAGCTTCTCCTTAATGTCACGC  PCR 
m+h actin rev 5’- TGGCACCACACCTTCTACAATGAGC  PCR 
h BCL9-2 fwd 5’- AATCATGGCAAGACAGGGAATGGCT  
PCR, qRT-
PCR 
h BCL9-2 rev 5’- TCTTCAGACTTGAGTTGCTAGGCG  
PCR, qRT-
PCR 
h β-catenin fwd 5’- TTCGAAATCTTGCCCTTTGTCCCG  qRT-PCR 
h β-catenin rev 5’- AATTCGGTTGTGAACATCCCGAGC  qRT-PCR 
h ESR1 fwd 5’- GCATTCTACAGGCCAAATTCA  qRT-PCR 
h ESR1 rev 5’- TCCTTGGCAGATTCCATAGC  qRT-PCR 
h PGR fwd 5’- TCCACCCCGGTCGCTGTAGG  qRT-PCR 
h PGR rev 5’- TAGAGCGGGCGGCTGGAA GT  qRT-PCR 
h GREB1 fwd 5’- GTGGTAGCCGAGTGGACAAT  qRT-PCR 
h GREB1 rev 5’- ATTTGTTTCCAGCCCTCCTT  qRT-PCR 
h β-actin fwd 5’- ATAGCACAGCCTGGATAGCAACGTAC  qRT-PCR 
h β-actin rev 5’- CACCTTCTACAATGAGCTGCGTGTG  qRT-PCR 
h pESR1-158+40 fwd 5’- GGGAAGCTGCTCTTTGGGAT  PCR 
h pESR1-158+40 rev 5’- AAGTGCAGTCCCAGGACGA  PCR 
h pESR1-312-130  fwd 5’- ACATTAGAGAAAGCCGGCCC  PCR 
h pESR1-312-130 rev 5’- TTGGAGCGATCCCAAAGAGC  PCR 
h pESR1-3813-3700 
fwd 
5’- CACAGACACGGGGAAGTTGA  
PCR 
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h pESR1-3813-3700 
rev 
5’- TTGAATGTGTCTCCAGCCCC  
PCR 
h pESR1+26+145 fwd 5’- CTGGGACTGCACTTGCTCC qRT-PCR 
h pESR1+26+145 rev 5’- GAGGTTAGAGGCGACGCAG qRT-PCR 
h pESR1-268 -195 fwd 5’- TTAAGCCCAGTCTTCCCTGG qRT-PCR 
h pESR1-268 -195 rev 5’- AGGCTGAGTTTCACGGCCA qRT-PCR 
h pGAPDH -145+21 
fwd 
5'- TACTAGCGGTTTTACGGGCG  
PCR, qRT-
PCR 
h pGAPDH -145+21 
rev 
5'- TCGAACAGGAGGAGCAGAGAGCGA  
PCR, qRT-
PCR 
ESR1 WT fwd 5’- GCGGTACCCCTTTAGCAGATCCTCGTGC cloning 
ESR1 WT rev 5’- GCTCGAGTGCAGACCGTGTCCCCGCAGG cloning 
ESR1 MT-B fwd 
5’- 
GCGGTACCCCTTTAGCAGATCCTCGTGCGCC 
GGAATTCCGGGGCCGTGAAA 
cloning 
ESR1 MT-A fwd 
5’- 
CGCAGGCTCCCGCGGAATTCCGCCGGCCAGA 
GCT 
cloning 
ESR1 MT-A rev 
5’- 
AGCTCTGGCCGGCGGAATTCCGCGGGAGCCT 
GCG 
cloning 
 
Supplemental Table 4:Scoring of the preneoplastic changes of the mammary gland. 
Score Duct 
dilatation 
Alveolar 
differentiation 
Hyperplastic Alveolar 
Nodules (size) 
Score Amount of 
tissue affected 
0
 none no alveoli None 0
 0% 
1 moderate  moderate  < 0,5 mm  1 < 30% 
2 strong strong 0,5 - 0,75 mm  2 30% – 60% 
3 severe severe > 0,75 mm  3 > 60% 
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